June 25th 2025
Researchers explored the prevalence of obesity-related complications and obesity medication use in US children and young adults with obesity.
Revita is a procedure that modifies duodenal dysfunction and restores metabolic health, according to Fractyl Health.
June 24th 2025
In a retrospective study of obesity-related mortality, researchers explored US death trends before, during, and after the COVID-19 pandemic.
In a real-world, 6-month analysis, glucagon-like peptide-1 programs with obesity telemedicine behavioral programs resulted in benefits to weight loss and blood pressure.
June 18th 2025
The program will include branded obesity glucagon-like peptide-1 medications, which will have a transparent monthly cost.
Eli Lilly Adds Highest Doses of Zepbound to Online Pharmacy Platform
Providers can prescribe the 12.5 mg and 15 mg vials of tirzepatide starting July 7, with shipments beginning in early August.
Healthy Diet Provides Health Benefits, Even Without Weight Loss
Investigators find that patients with moderate weight loss or those who were weight resistant still had improvement in cardiometabolic health.
Statins Have No Additional Antidepressive Effects as Add-On Treatment
Investigators found that simvastatin added to escitalopram for patients with obesity and major depressive disorder did not have increased antidepressive effects.
Semaglutide, Antibody Combination Protects Lean Mass During Weight Loss
Results from a phase 2 trial showed that semaglutide combined with trevogrumab, with or without garetosmab, helped patients preserve lean mass and achieve greater fat loss.
Sustained Midlife Weight Loss Linked With Long-Term Health Benefits
The data show a decrease in all-cause mortality for sustained midlife weight loss achieved without surgical or pharmacological interventions.
Evernorth Benefit Option Will Cap Wegovy, Zepbound Monthly Cost at $200
The new program aims to reduce costs for patients, with savings estimated at as much as $3600 per year.
GLP-1 Usage Does Not Increased Risk of Psychiatric Events, Study Finds
Glucagon-like peptide-1 receptor agonists have been associated with improvements in quality of life (QOL), restrained eating, and emotional eating behavior.
Online Obesity Clinics Report Consistent Weight Loss With Lower Doses of Semaglutide
Investigators report that patients experience weight loss with a reduced weekly dosage of the glucagon-like peptide-1 (GLP-1).
Wegovy Shows Early Reduction in Major Adverse Cardiovascular Events
Semaglutide resulted in a significant reduction in the risk of MACE within the first 3 months of treatment compared to placebo.
Tirzepatide Shows Superior Weight Loss Over Semaglutide in Phase 3 Trial
Tirzepatide (Zepbound) demonstrated superiority compared to semaglutide (Wegovy) across the primary end point and 5 key secondary end points.
Calories to Satiation Predicts Patients Likely to Experience Adverse Events From GLP-1s
Patients often have anxiety about potential adverse effects, and experiencing adverse effects can affect patient adherence.
CVS Caremark Makes Wegovy Preferred Weight-Loss Medication
The nation’s largest PBM is placing Novo Nordisk’s premier weight-loss drug atop its formulary beginning July 1, 2025.
Projection Estimates GLP-1 Market to Nearly Double by End of Decade | Asembia 2025
Although the market is expected to continue to become more popular, compounding pharmacies will no longer be allowed to manufacture these medications, as shortages have been listed as resolved.
GLP-1 Medications Continue to Increase Market Growth | Asembia 2025
Glucagon-like peptide-1 medications are the fastest-growing class of medication and will continue to be prevalent as more indications, such as sleep apnea, are added.
American Diabetes Association Issues Updates to Standards of Care in Diabetes for 2025
The authors emphasize the importance of multifaceted and team-based approaches to the management of diabetes.
Q&A: Expert on Social Media’s Normalization of Lifestyle Drugs
Luke Turnock, PhD, MSc, discussed current trends in the promotion of lifestyle enhancement drugs for populations they are not approved for.
Pfizer Discontinues Development of Investigational Oral GLP-1 for Weight Management
One asymptomatic patient did experience drug-induced liver injury that was resolved after discontinuation of danuglipron.
Data Show Neural Mechanisms Between Obesity and Cognition
Investigators find 5 distinct obesity trajectories that influenced brain morphology, function, and cognition.
FDA Approves Generic Liraglutide for Type 2 Diabetes
As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.
Procedure Helps Prevent Weight Regain After Discontinuation of GLP-1 Medication
The outpatient endoscopic procedure modifies duodenal dysfunction and restores metabolic health.
Q&A: Pharmacist Strategies for Optimizing GLP-1 Therapy Outcomes
Lydia Newsom, PharmD, discusses injection techniques, managing side effects, and the importance of collaboration between the healthcare team.
Q&A: Pharmacists’ Role in GLP-1 Diet, Exercise Counseling
Lydia Newsom, PharmD, discuses how pharmacists can support patients using GLP-1s.
Semaglutide, TRT Advertising Contributing to Normalization of Use
Researchers explored how social media advertising of lifestyle drugs contributes to the normalization of use for semaglutide, testosterone, and sildenafil.
Social Determinants Crucial in Obesity Prevention, Treatment
On both an individual and societal level, researchers explored how social, cultural, and ethnic determinants impact the treatment and management of obesity.
Tirzepatide, Semaglutide Show Long-Term Benefits, But Are Not Cost-Effective
Tirzepatide and semaglutide show long-term health care cost savings but, the high cost of the medications offset the savings.
Weight, Diabetes Status Significantly Influence Perceptions of Food
Among various weights and diabetes diagnoses, researchers explored the differences in patients’ food perceptions when considering weight management and appetite.
Healthier Diet, Lower WHR Improved Cognitive Brain Function
Researchers compared changes in diet quality and waist-to-hip ratio during midlife with that of hippocampal connectivity and cognitive function in later life.
CagriSema Demonstrates Significant Weight Loss at 68 Weeks
Approximately 89.7% of patients taking CagriSema achieve the coprimary end point of weight loss of 5% or more compared with 30.3% on the placebo.
Reduction in Waist Circumference Led to Lower All-Cause Mortality
Among postmenopausal women, researchers explored associations between intentional weight loss and waist circumference (WC) reduction and mortality.
Mediterranean Diet Adherence Reduced Risk of Obesity-Related Cancer
Researchers analyzed the association between adherence to a Mediterranean diet and obesity cancers, with a focus on the mediating role adiposity plays throughout the process.